Eupraxia (EPRX) news
Recent news
Fitch affirms Epif at 'BBB'; outlook stable
Fitch Ratings has affirmed its credit rating for Epif at 'BBB', with a stable outlook, reflecting the company's solid financial position and operational performance. The rating underscores Fitch's confidence in Epif's ability to maintain its creditworthiness amid evolving market conditions. The…
AInvest Wire · 21h agoEpiroc AB: Barclays raises target price to SEK 285 from SEK 280
Barclays has raised its target price for Epiroc AB (EPI.A) to SEK 285 from SEK 280, reflecting the firm’s confidence in the company’s operational performance and market positioning. The adjustment, while modest, underscores the analyst’s view of Epiroc’s strong fundamentals and continued growth in…
AInvest Wire · 1d agoEupraxia Pharmaceuticals - EP-104GI cohort 8B shows EoEhss stage -0.26 and grade -0.27 reduction at 36 weeks
AInvest Wire · Sep 30, 2026Eupraxia Pharmaceuticals - EP-104GI highest dose cohort shows 66% clinical remission at 52 weeks
AInvest Wire · Sep 30, 2026Eupraxia Pharmaceuticals Inc: Wedbush initiates coverage with outperform rating; price target $17
Wedbush Securities has initiated coverage on Eupraxia Pharmaceuticals Inc. (NASDAQ: EUPR), assigning the stock an "Outperform" rating with a price target of $17 per share. The decision reflects the firm’s assessment of the company’s therapeutic pipeline and potential for growth in the oncology and…
AInvest Wire · Sep 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.